Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020093053 - BIVALENT TARGETED CONJUGATES

Publication Number WO/2020/093053
Publication Date 07.05.2020
International Application No. PCT/US2019/059687
International Filing Date 04.11.2019
IPC
A61K 31/7088 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61K 47/54 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
C12N 15/113 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants
  • ARBUTUS BIOPHARMA CORPORATION [CA]/[US]
  • HEYES, James [GB]/[CA]
  • HOLLAND, Richard J. [CA]/[CA]
  • PALMER, Lorne Ralph [CA]/[CA]
  • WOOD, Mark [CA]/[CA]
Inventors
  • HEYES, James
  • HOLLAND, Richard J.
  • PALMER, Lorne Ralph
  • WOOD, Mark
Agents
  • MALEN, Peter L.
  • HARRIS, Robert J.
  • VIKSNINS, Ann S.
  • ANDRUS, Alex
  • MICKELSON, John W.
  • KRUEGER, Katherine A.D.
  • NIU, Lin
  • PADYS, Danny J.
Priority Data
62/755,17902.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIVALENT TARGETED CONJUGATES
(FR) CONJUGUÉS CIBLÉS BIVALENTS
Abstract
(EN)
The invention provides conjugates that comprise a bivalent targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates, compositions comprising the bidentate targeting ligands and the conjugates, as well as methods for targeting therapeutic nucleic acids with the bidentate conjugates. The conjugates are useful to target therapeutic nucleic acids.
(FR)
L'invention concerne des conjugués qui comprennent une fraction de ciblage bivalente, un acide nucléique et éventuellement des groupes de liaison ainsi que des intermédiaires synthétiques et des procédés de synthèse utiles pour préparer les conjugués, des compositions comprenant les ligands de ciblage bidentés et les conjugés, ainsi que des procédés de ciblage d'acides nucléiques thérapeutiques avec les conjugués bidentés. Ces conjugués sont utiles pour cibler des acides nucléiques thérapeutiques.
Latest bibliographic data on file with the International Bureau